Harbourvest Partners’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,451,876
| Closed | -$5.69M | – | 59 |
|
|
2023
Q3 | $5.69M | Buy |
1,451,876
+1,298,701
| +848% | +$8.86M | 1.93% | 10 |
|
|
2023
Q2 | $498K | Hold |
153,175
| – | – | 0.14% | 44 |
|
|
2023
Q1 | $554K | Hold |
153,175
| – | – | 0.19% | 44 |
|
|
2022
Q4 | $4.93M | Hold |
153,175
| – | – | 1.65% | 10 |
|
|
2022
Q3 | $6.4M | Hold |
153,175
| – | – | 2.09% | 12 |
|
|
2022
Q2 | $6.46M | Hold |
153,175
| – | – | 2.12% | 12 |
|
|
2022
Q1 | $10.4M | Hold |
153,175
| – | – | 2.12% | 10 |
|
|
2021
Q4 | $18.6M | Hold |
153,175
| – | – | 2.38% | 8 |
|
|
2021
Q3 | $21.6M | Hold |
153,175
| – | – | 2.03% | 8 |
|
|
2021
Q2 | $42.1M | Hold |
153,175
| – | – | 4.02% | 5 |
|
|
2021
Q1 | $32.8M | Hold |
153,175
| – | – | 4.4% | 4 |
|
|
2020
Q4 | $37M | Hold |
153,175
| – | – | 14.47% | 2 |
|
|
2020
Q3 | $16.1M | Hold |
153,175
| – | – | 5.97% | 3 |
|
|
2020
Q2 | $15M | Buy |
153,175
+65,000
| +74% | +$5.69M | 6.47% | 3 |
|
|
2020
Q1 | $6.62M | Hold |
88,175
| – | – | 3.2% | 5 |
|
|
2019
Q4 | $7.16M | Hold |
88,175
| – | – | 2.95% | 5 |
|
|
2019
Q3 | $10.8M | Hold |
88,175
| – | – | 4.47% | 3 |
|
|
2019
Q2 | $15.8M | Hold |
88,175
| – | – | 5.8% | 3 |
|
|
2019
Q1 | $14.1M | Hold |
88,175
| – | – | 4.99% | 4 |
|
|
2018
Q4 | $22.9M | Hold |
88,175
| – | – | 10.87% | 2 |
|
|
2018
Q3 | $21.5M | Hold |
88,175
| – | – | 19.42% | 2 |
|
|
2018
Q2 | $20.8M | Buy |
+88,175
| New | +$25.7M | 26.29% | 1 |
|
Other funds holding EVLO
Harbourvest Partners's EVLO Position: Q4 2023 in Review
Harbourvest Partners sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 1,451,876 shares — an estimated $5.69M sold.
Harbourvest Partners first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $42.1M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Harbourvest Partners reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Harbourvest Partners sold 1,451,876 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $5.69M.
- Harbourvest Partners first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Harbourvest Partners's Evelo Biosciences, Inc. Common Stock position peaked at $42.1M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Harbourvest Partners's 13F filing for Q4 2023, filed 14 Feb 2024.